Skip to main content
Premium Trial:

Request an Annual Quote

PGDx PlasmaSELECT 64 Panel

Personal Genome Diagnostics has launched its PlasmaSELECT 64 panel for pan-cancer tumor profiling. The CLIA-validated pan-cancer plasma assay incorporates the company's PARE and Digital Karyotyping technologies combined with VariantDX computational algorithms to identify sequence mutations with exceptional accuracy. The assay looks at genes shown to have biological and functional relevance to aid physicians making treatment decisions, and includes 15 unique biomarkers — 11 of which are associated with active clinical trials, the company said.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.